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Abstract Antibody-mediated rejection (AMR) is a unique,
significant, and often severe form of allograft rejection that
is not amenable to treatment with standard immuno-
suppressive medications. Significant advances have oc-
curred in our ability to predict patients at risk for, and to
diagnose, AMR. These advances include the development
of newer anti-human leukocyte antigen (HLA)-antibody
detection techniques and assays for non-HLA antibodies
associated with AMR. The pathophysiology of AMR
suggests a prime role for antibodies, B cells and plasma
cells, but other effector molecules, especially the comple-
ment system, point to potential targets that could modify
the AMR process. An emerging and potentially larger
problem is the development of chronic AMR (CAMR)
resulting from de novo donor-specific anti-HLA antibodies
(DSA) that emerge more than 100 days posttransplantation.
Therapeutic options include: (1) High-dose intravenously
administered immunoglobulin (IVIG), which has many
potential benefits. (2) The use of IVIG + rituximab (anti-
CD20, anti-B cell). (3) The combination of plasmapheresis
(PP) + low-dose IVIG with or without rituximab. Data
support the efficacy of all of the above approaches. Newer
approaches to treating AMR include using the proteosome
inhibitor (bortezomib), which induces apoptosis in plasma
cells, and eculizumab (anti-C5, anticomplement monoclonal
antibody).
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Introduction
Renal transplantation is well recognized as the treatment of
choice for end-stage renal disease (ESRD), as it offers
improved quality of life and survival [1–3]. As a result, the
demand for donor kidneys continues to outpace the supply.
There are more than 83,153 ESRD patients on the
deceased-donor waiting list, and almost 32,000 new
patients register annually; yet fewer than 18,000 kidney
transplants are performed each year [based on US Depart-
ment of Health and Human Services Organ Procurement
Transplant Network (OPTN) data as of 30 January 2009]
[4]. As the demand for organs continues to exceed the
supply, the number of days spent waiting for a kidney
transplant increases exponentially, particularly for patients
who are difficult to match secondary to having broadly
reactive human leukocyte antigen (HLA)-specific allo-
antibodies. Patients sensitized to HLA antigens account
for approximately 30% of the transplant list. Recent data
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(2001–2008) [5] show that rates of living-donor (LD) and
deceased-donor (DD) transplantation by panel-reactive
antibody (PRA) status are <16% per year for patients with
PRAs 10–80%, and <8% for patients with PRAs >80%.
Clearly, any level of sensitization poses a challenge for
successful transplantation due to the powerful barrier that
preformed anti-HLA antibodies and immunologic memory
represent.
Desensitization protocols for highly sensitized (HS) and
ABO (blood group)-incompatible patients [6–13]h a v e
improved transplant rates and long-term patient and
allograft survival in this high-risk population. However,
these patients are at higher risk for antibody-mediated
rejection (AMR). The incidence of AMR after desensitiza-
tion treatments is approximately 30% [6, 7, 9–13], thus
necessitating development of novel techniques for early
diagnosis and approaches to AMR treatment.
AMR is not an uncommon complication of transplanta-
tion, especially in centers performing desensitization. The
immediate loss of allografts due to hyperacute AMR is rare
due to advancements in anti-HLA antibody detection and
ABO matching. However, new-onset AMR can occur
within hours of transplantation and is usually manifest by
a rapid onset of allograft dysfunction associated with high
resistivity indices on Doppler renal ultrasound and
increases in donor-specific antibodies (DSA). This constel-
lation of findings indicates a true medical emergency for
the patient, especially if the allograft is to be salvaged.
Treatment approaches have changed little since our last
review [14], but there have been many refinements in our
understanding of pathogenesis and in monitoring the
efficacy of therapies, data on combination therapies, and
new drugs that could possibly make a significant impact on
AMR in the future. In this review, we discuss advances in
the diagnosis and treatment of AMR that have occurred
since our last review.
Advancements in detecting anti-HLA antibodies
Solid-phase antibody testing has greatly advanced the ability
to characterize the presence and specificity of HLA-specific
antibodies. These assays have eliminated many problems
encountered with cell-based antibody testing methods,
including eliminating the need for viable cells, identifying
only HLA-specific antibodies—both complement-fixing and
non-complement-fixing antibodies—and clearly identifying
class-I versus class-II-specific antibodies. There are two
types of solid-phase HLA-specific antibody screening
methods: an enzyme-linked immunosorbent (ELISA)-based
system and color-coded bead-based fluorometric assays.
Both methods use soluble HLA antigens captured onto either
a microtiter plate or beads. Fluorometric-based assays
include detecting the beads by the flow cytometer or by the
Luminex-based method. As this method is more sensitive
than the ELISA method, we focused our testing approach to
use mainly the Luminex-based method. There are still issues
that must be considered in interpreting results generated by
these assays. Antigen concentration on the beads may be
higher than on cells; antigen density varies among beads;
beads of some antigen groups may be overexpressed relative
to other groups; antigens on beads may not be in a natural
conformation, resulting in cryptic epitopes; and there can be
variation between lots and between vendor products.
Compared with the cell-based method, the fluorometric bead
system is not as susceptible to drug interference, such as
antithymocyte globulin, intravenously administered immu-
noglobulin (IVIG), and rituximab. IVIG may interfere with
the bead assay for a few days after administration.
Nonetheless, these new techniques allow for greater identi-
fication of HLA antibody specificities and a more accurate
interpretation of cross-match results.
Despite these limitations, advancements in solid-phase
detection of HLA class I/II antibodies and non-HLA-
directed antibodies [i.e. major histocompatibility complex
class I-related chain A (MICA)] have greatly improved our
understanding of sensitization and the impact of desensiti-
zation protocols on antibody levels. Most advanced HLA
laboratories are evolving practices to determine the best
combination of assays that can be used to monitor
desensitization efficacy and/or AMR treatment.
The ability to predict the AMR risk using newer solid-
phase assays is not yet established. The established
pathological criteria for diagnosing AMR (C4d deposition,
allograft dysfunction, and pathologic features of inflamma-
tion) are still regarded as the cornerstones required for
AMR diagnosis [15]. There are several reports indicating a
close association between anti-HLA antibody detection and
the presences of AMR [16–18]. However, the relationship
is far from clear. Most investigators believe that DSA titers
are most predictive of AMR risk, but others have seen a
less well established relationship between DSA detection
and AMR risk [16–18]. This includes data from our group
[7]. Despite these limitations, Reinsmoen et al. recently
reported on attempts to develop a paradigm to predict AMR
risk in patients undergoing desensitization [19].
Critical to the success of desensitization protocols and
predicting AMR is the monitoring of antibody levels
[15, 20–24]. Achieving acceptable DSA levels that allow
for successful transplantation post desensitization and
permit long-term graft function with a decreased risk for
AMR are critical. Zachary et al. [24] have shown the initial
titer and specificity of DSA are critical in determining the
likelihood of successful desensitization. Quantitative solid-
phase antibody methodologies have allowed for a more
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the desensitization protocols and sensitivity to predicting
AMR. Our group [15] recently showed that the strength of
DSA as detected by a sensitive quantitative DSA tests
allowed for successful transplantation after desensitization
treatment with high-dose IVIG and rituximab and identi-
fication of patients at higher risk for AMR. Posttransplant
DSA monitoring using this technique also identified
points for therapeutic intervention aimed at improving
early AMR diagnosis and potentially improving graft
outcomes.
Although these values can be used as guidelines, the
relevant cutoff values for each center need to be based on
the immunosuppression and desensitization protocols
implemented at that particular center and that program’s
ability to handle high-risk patients. There are technical as
well as immunosuppression protocol-dependent factors that
influence the cutoff values, which must be established by
each transplant center [20–23]. These results show that
successful transplantation can be achieved with acceptable
DSA levels. Our results are consistent with those of
Zachary et al. [24], who reported that titer and specificity
influenced the efficacy of desensitization protocols and
transplant outcome. In our study, antibody strength
appeared to be critical in determining the level at which
successful transplantation could be accomplished. This
approach is summarized in Figs. 1 and 2.
Further, levels of DSA >10
5 standard fluorescent
intensity (SFI) indicated the need for close posttransplant
monitoring of antibody level and specificity. The posttrans-
plant assessment of antibody course and specificity showed
that patients without immune complications had similar
antibody profiles. Patients with DSA levels <10
4 SFI units
were at low risk for AMR, as were patients with DSA SFI
between 10
4 and 10
5 with pretransplant cross matches
<200 mean channel shifts (MCS). Both DSA and third-
party antibody levels continued to decrease, eventually to
below the 10
4 level considered to be flow cross-match
negative. These patients’ antibody courses were monitored
weekly for the first month posttransplantation and then
monthly for 3 months. Patients with DSA >10
5 and donor-
specific cross matches >200 MCS were considered at high
risk for AMR and warranted more frequent antibody-level
monitoring posttransplantation [15]. Figure 1 a and b shows
the DSA course for two highly HLA-sensitized patients.
Both were desensitized with IVIG + rituximab. The patient
shown in Fig. 1a demonstrates an excellent response to
desensitization therapy with elimination of DSA levels.
This was associated with a rejection-free course. The
patient depicted in Fig. 1b had reductions in DSA levels
that allowed LD transplantation, but AMR episode occurred
3 months posttransplant that was associated with an
increase in DSA. Retreatment resulted in reduction in
DSA to HLA A2 but not DR53. The patient had a good
clinical response and was nearly 2 years posttransplant at
the time of writing, with serum creatinine 1.4 mg/dl and no
proteinuria. Figure 2 summarizes the relationship among
flow cytometry cross matches, complement-dependent
cytotoxicity cross matches, and DSA. Briefly, we aim to
reduce DSA levels to ≤100,000 SFI units to allow
transplant to go forward. This is usually associated with a
low risk of AMR. Posttransplant DSA monitoring allows us
Fig. 1 a Donor-specific antibody (DSA) pattern for a highly human
leukocyte antigen (HLA)-sensitized patient who had awaited
deceased-donor (DD) transplantation for >10 years. The patient was
treated with intravenously administered immunoglobulin (IVIG) +
rituximab as per protocol and received a DD transplantation shortly
after completing desensitization. DSA levels rapidly decreased from
>200,000 standard fluorescent intensity (SFI) units to unmeasurable.
At the time of writing this article, the patient was >1 year posttrans-
plant without antibody-mediated rejection (AMR), with a serum
creatinine (Cr) 0.8 mg/dl. b DSA pattern from a patient who received
a living-donor (LD) kidney transplant approximately 2 years ago. The
patient exhibited DSAs to A2, DR53, and DQ6. After desensitization,
good responses were seen, which allowed transplantation. Approxi-
mately 3 months posttransplant, the patient experienced AMR, with an
increase in DSAs. These responded somewhat to IVIG + rituximab
treatment. Serum Cr was stable at 1.4 mg/dl for 2 years, and no
proteinuria has been observed
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SFI units, as these are very predictive of AMR episodes.
Lefaucher et al. [18] have shown that DSA at transplan-
tation is a significant risk factor for AMR compared with
patients without DSA (34.9% vs 3.1%, p<0.0001). Eight-
year graft survival was also less in the DSA+ vs DSA−
group (67.9% vs 77.3%, p=0.03). However, there was no
difference in 8-year graft survival between patients in the
DSA+ group who did not develop AMR vs those in the
DSA− group (78.5% vs 77.3%, p=NS). These data are
intriguing, as DSA presence alone was not a risk factor for
long-term graft loss. These investigators also showed that
DSA strength was significantly associated with AMR risk.
In addition, recent data [17, 18] point to the importance of
DSA monitoring during AMR onset as a predictive factor
for responses to therapy.
This work has added to our understanding of how a
combination of anti-HLA/DSA determinations can help
predict posttransplant AMR risk. We use this paradigm in
allocating organs to our highly HLA-sensitized patients
who have completed desensitization. Of interest in our
patient population is that most patients are transplanted
with positive cross matches [T-cell flow cytometry cross
match (FCMX)/B-cell FCMX] and have detectable DSA.
However, only 23% have AMR episodes, suggesting that
the desensitization protocols are likely altering other
immune effector mechanisms responsible for the AMR
process. Thus, DSA and other non-HLA-directed antibodies
are a critical marker of sensitization and AMR risk but are
not the sole mediators of this process. DSA titer appears to
be the best marker for AMR risk, but clearly, other effector
pathways, including complement activation and cell-
mediated immunity with memory capacity that are not yet
clearly defined, likely play an important role in increasing
the risk for AMR development.
Non-HLA antibodies mediating AMR
Endothelial cells express a number of antigens not present on
lymphocytes,whichcouldbetargetsofpreformedantibodies
and result in AMR. Recently, antibodies reactive with non-
HLA target antigens expressed on donor endothelium have
received closer attention as AMR mediators [25–29]. Our
work and that of others have shown that antibodies directed
at endothelial cell targets [antiendothelial cell antibody
(AECA)] can damage endothelial cells and are closely
associated with rejection episodes and poor graft survival in
cardiac and kidney transplant recipients [25, 26]. It is also
of interest that cytomegalovirus (CMV) infection is a potent
inducer of polyclonal AECA responses in cardiac and renal
allograft recipients [26]. Figure 3 shows this association
and the outcomes of AECA + vs AECA–cardiac allograft
recipients at 2 years [25]. Despite these early findings, the
Fig. 2 Relationship among donor-specific antibody (DSA), flow
cytometry cross match (FCMX) results and risk for antibody-mediated
rejection (AMR) in patients desensitized with intravenously adminis-
tered immunoglobulin (IVIG) + rituximab. We show that reduction,
but not elimination, of DSA to levels of ~100,000 standard fluorescent
intensity (SFI) correlates with a FCMX of ~200–225 mean channel
shifts (MCS). This usually allows transplantation of highly human
leukocyte antigen (HLA)-sensitized patients with a low risk of AMR.
However, patients who demonstrate DSA 100,000–200,000 SFI and
FCMX >250 channel shifts (CS) are more likely to experience AMR.
Patients who demonstrate complement-dependent cytotoxicity (CDC+)
cross matches have FCMXs >300 MCS and DSA levels >200,000.
These patients are at an extremely high risk for AMR if transplanted.
The line shows the hypothetical relationship between DSA and FCMX
results. A normal FCMX is defined as 50 CS or less and an SFI DSA
level of 10,000 or less
Fig. 3 Outcomes of cardiac transplant recipients followed for
>2 years. Patients were divided into those who had persistent
demonstration of antiendothelial cell antibody (AECA+) posttrans-
plant vs patients who never demonstrated positivity (AECA−)
posttransplant. The importance of non-human leukocyte antigen
(non-HLA) antibodies directed at endothelial cell targets not present
on lymphocytes can cause antibody-mediated rejection (AMR) and
graft loss [25]
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However, recent data suggest that a major target on
endothelium is the angiotensin type 1 receptor (AT1R).
Dragun et al. [27] recently identified AT1R antibodies in 16
patients who experienced severe AMR associated with
malignant hypertension who did not have detectable anti-
HLA antibodies. Indeed, we have patients who had similar
presentations and who ultimately lost allografts from AMR
without developing anti-HLA antibodies (Reinsmoen et al.
unpublished results). Malignant hypertension with rapid
onset of allograft dysfunction and thrombosis was also seen
in these patients. Standard treatment with antilymphocyte
globulin and high-dose steroids was ineffective. The
efficacy of other therapies, including plasmapheresis, IVIG,
and rituximab is unknown. The incidence and prevalence of
AT1R antibodies in patients awaiting kidney transplantation
is currently unknown. However, this could be an important
assessment for patients, as newer, more rapid, diagnostics
will soon be available [28, 29].
Anotherimportantpolymorphic antigen system expressed
on endothelium is MICA. These antigens bind to NKG2D
and are important in natural killer cell activation, thus
playing and important role in innate immunity [30]. Recent
data [31] suggest that kidney transplant recipients, espe-
cially retransplant recipients, demonstrating MICA anti-
bodies had inferior allograft survival rates compared with
non-MICA-positive patients. These data expand the need to
test potential kidney recipients for MICA antibodies to
prevent AMR. Of note, MICA antibodies are usually not
complement activating; thus, biopsies may be C4d- [30,
31]. Recent reports also describe a novel flow cytometric
test that detects antibodies directed against donor-specific
endothelial cells [28]. These investigators use beads coated
with antibodies to the endothelial cell antigen Tie-2 to
isolate circulating endothelial cell precursors from the
peripheral blood of potential donors. A simultaneous T-
cell, B-cell, and donor-specific endothelial-cell cross match
can be performed. Although initial data are interesting, the
broader application of this technique will require verifica-
tion that detection of antibodies to endothelial-specific
antigens (i.e. MICA and AT1R antibodies) can be done
reliably and will add to AMR prevention.
Treatment options for patients with AMR
Intravenously administered immunoglobulin (IVIG)
IVIG is now recognized as an important “natural” regulator
of immunity and inflammation [32–36]. IVIG has become
an essential element of all desensitization and AMR
treatment protocols, although the exact mechanism(s) of
action are not well defined. Recent data suggest that
modification of complement activation and cell-mediated
immunity are critical components of the anti-inflammatory
and immunoregulatory actions of IVIG [37–39].
Modification of complement-mediated injury by IVIG
Immunoglobulin molecules are known for their ability to
activate complement as part of the body’s innate defense
mechanism against invading pathogens [32–36]. However,
the concept that Ig molecules can also inhibit complement
activation and “scavenge” anaphylatoxins and active
complement components has only recently been identified
[32, 37–42]. Preincubation of C3a/C5a with F(ab)’2 frag-
ments of IgG results in binding and inhibition of inflam-
matory activity [42]. The Fc fragment of IgG molecules
also shows significant ability to bind to C3b and C4b. Data
from an experimental model of stroke injury shows that
animals pretreated with IVIG or treated within 1–2 h post
ischemia/reperfusion (I/R) injury had significant reductions
in infarct size compared with control animals. It was also
demonstrated that the major mediator of I/R injury in the
brain was complement and that IVIG was a powerful
scavenger of C3b produced in the ischemic brain [32, 37–
42]. IVIG treatment has also shown efficacy in limiting
antibody-mediated complement activation in several other
experimental models [32, 42]. These observations have
clear implications for preventing and treating AMR.
Regulation of cell-mediated immunity by IVIG
One of the most important findings regarding immune
regulation by IVIG is recent evidence that IVIG actually
induces the critical inhibitory receptor FcγRIIb on immune
cells [32–36]. Ravetch et al. [43–47] have shown that the
beneficial effects of IVIG can actually be recapitulated by
recombinant immunoglobulin G (IgG) Fc fragments. These
investigators postulate that the anti-inflammatory activity of
intravenously administered Ig (IVIG) results from a minor
population of the pooled IgG molecules that contains
terminal alpha 2,6-sialic acid linkages on their Fc-linked
glycans. They have also shown that the anti-inflammatory
properties can be recapitulated in mouse models with a
fully recombinant preparation of appropriately sialylated
IgG Fc fragments. More importantly, the authors have
recently demonstrated that these sialylated Fcs bind to
a specific C-type lectin, SIGN-R1 (specific ICAM-3
grabbing non-integrin-related 1) expressed on macrophages
in the splenic marginal zone in mice. Splenectomy, loss of
SIGN-R1(+) cells in the splenic marginal zone, blockade of
the carbohydrate recognition domain (CRD) of SIGN-R1,
or genetic deletion of SIGN-R1 abrogated the anti-
inflammatory activity of IVIG or sialylated Fc fragments.
A human ortholog of SIGN-R1, DC-SIGN, displays a
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cellular distribution, potentially accounting for some of the
species differences observed in IVIG efficacy. These
studies are important since they are the first to identify a
receptor for sialylated Fcs. Recombinant sialylated Fcs or
IVIG products enriched for sialylated IgG molecules could
represent potential therapeutic agents that could eventually
replace IVIG since sialylated Fc population shows equal
efficacy to IVIG in significantly reduced dose levels [45–47].
To date, these experiments have only been conducted in
animal models and their application to human disease is still
questionable [36]. Despite these concerns, this body of work
represents a major advancement in our understanding of how
IVIG regulates cell-mediated immunity and how IVIG works
to regulate alloimmune responses.
Use of IVIG for treating AMR
Our group was the first to report on the use of IVIG for
treating AMR in kidney and heart allograft recipients with
antibody-mediated rejection [48]. Although this experience
is now more than a decade old, it was useful in showing
that AMR episodes could respond to IVIG and pulse
methylprednisolone, although the mechanism(s) of action
was not appreciated at that time. The first patient treated
with high-dose IVIG for resistant rejection (1994) had
failed OKT3 therapy and two courses of pulse methyl-
prednisolone. The features of AMR were not appreciated at
that time, but the patient was noted to develop a positive
posttransplant complement-dependent cytotoxicity (CDC)
cross match with donor cells that showed in vitro inhibition
with IVIG. The decision to treat with high-dose IVIG was
based on this observation and the patient’s unresponsive-
ness to other treatments. The patient had a dramatic
response to IVIG treatment, with serum creatinine decreas-
ing from 3.0 mg/dl to 1.0 mg/dl over 3–4 days. The patient
had no further AMR episodes and has a serum creatinine
1.7 mg/dl 15 years posttransplant. At that time, we felt this
represented a major new approach to cross-match-positive
rejection episodes, and other patients were treated with
high-dose IVIG for severe rejection episodes associated
with cross match positivity, as described [14, 48]. Other
groups have also described the benefits of high-dose IVIG
in treating resistant AMR episodes [18, 49, 50]. IVIG +
pulse methylprednisolone with/without plasma exchange
was used as our primary treatment for AMR until 2004
[14]. Lefaucher et al. [51] recently reported on a retrospec-
tive comparison of high-dose IVIG alone (12 patients) vs
IVIG + rituximab + plasma exchange (12 patients) for
treating AMR. The IVIG-alone group was treated between
January 2000 and December 2003, whereas patients
receiving combined therapy were treated from January
2004 to December 2005. The investigators found that the
combined therapy was superior to IVIG alone in providing
improved graft survival at 36 months (91.7% combined vs
50% IVIG alone, p=0.02) and providing long-term sup-
pression of DSA levels. Although this is not a randomized
study and the number of patients is small, these findings
would support our own observations that led us to change
our approach to AMR treatment in 2004. What these
observations suggests is that combination therapies appear
to offer superior outcomes in terms of modification of DSA
levels and improving long-term allograft survival.
Rituximab for treating AMR
Rituximab is a chimeric anti-CD20 (anti B-cell) mono-
clonal antibody that is approved for treating lymphoma.
This antibody efficiently eliminates B cells, as the CD20
antigen is expressed early in B-cell ontogeny but is absent
on mature plasma cells [52]. Rituximab has also been
approved for use in rheumatoid arthritis and has demon-
strated significant benefit in a number of autoimmune and
inflammatory disorders [53–55]. Of note is the demonstrat-
ed benefit in vasculitic disorders that does not always
correlate with reduced pathogenic antibody [54, 55]. Recent
clinical data suggest that the beneficial effects of rituximab
may be due to depriving T cells of antigen-presenting cell
(APC) activity provided by antigen-specific B cells, thus
altering effector functions and inducing a regulatory profile
[56, 57]. These data suggest that the beneficial effects of
rituximab on autoimmune disease are more likely related to
modification of dysfunctional cellular immunity rather than
simply a reduction in antibody.
The variable region of rituximab binds to CD20 and
marks the cell for destruction by three different mecha-
nisms: antibody-dependent cell-mediated cytotoxicity
(ADCC), CDC, and cell-mediated apoptosis via CD20
cross-linking [52, 54]. ADCC occurs by binding of the Fc
portion of rituximab to Fcγ receptors on NK cells, macro-
phages, and monocytes. These cells then act to destroy the
B cell bound by the monoclonal antibody. CDC is mediated
by activation of the complement cascade by the Fc portion
of anti-CD20, ultimately resulting in the assembly of the
membrane attack complex and cell lysis. Finally, cross-
linking of bound CD20 protei n sc a u s e sa ni n f l u xo f
calcium, leading to activation of caspases resulting in cell
apoptosis.
Rituximab causes a profound and sustained depletion in
the number of circulating B cells. It also decreases B-cell
populations in lymph nodes and spleen. A recent study by
Genberg and colleagues evaluated the pharmacodynamics
after a single dose of rituximab (375 mg/m
2) in renal
transplant recipients [58]. B cell elimination was rapid,
occurred in the peripheral blood over 1−3 days, and was
prolonged. B-cell populations did not begin to reemerge
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is longer than what is observed in patients with lymphoma
or rheumatoid arthritis. Notably, B-cell lymphopenia was
present at baseline in the renal transplant population. The
delayed recovery of B cells may possibly be related to
maintenance immunosuppression. Rituximab also leads to a
significant reduction of B cells in lymph nodes, although
they were not completely eliminated. It is suggested that the
densely populated lymph node is more difficult to penetrate
and may require a higher dose of rituximab.
Elimination of some B-cell populations also occurs in
the spleen, but not uniformly. Ramos et al. demonstrated
the effect of rituximab in the spleens of individuals who
underwent desensitization [59]. These investigators quanti-
fied B cells in spleens removed from four groups of
patients: those who underwent splenectomy for trauma
(control group); those who underwent desensitization with
plasmapheresis (PP) low-dose IVIG with subsequent
splenectomy at the time of transplant (PP/IVIG group);
those who underwent desensitization with PP, low-dose
IVIG, and rituximab who also had a splenectomy at the
time of transplant (PP/IVIG/rituximab group); and those
who received rituximab, low-dose IVIG and rabbit anti-
thymocyte globulin (rATG) but not splenectomy (combina-
tion group). Splenectomy in the combination group was
done in the setting of refractory AMR and inadequate
response to PP prior to transplant. Naïve B cells (CD20+)
were significantly lower in the spleens of those who
received rituximab. There was no difference in CD20+ B-
cell depletion between the two rituximab-treated groups,
suggesting that the addition of rATG in the combination
group did not have an effect on this population of cells.
Plasma cells persisted despite treatment with rATG,
maintenance immunosuppression, and rituximab. The effect
on memory B cells (CD27+) is of interest. In the study by
Ramos et al., there was a trend toward a decrease in
memory B cells in the combination group compared with
the IVIG/PP/rituximab group [59]. From other studies, B-
cell depletion with rituximab is often associated with
delayed recovery of memory B cells (CD27+) and depletion
of pathogenic B cells [60, 61].
Rituximab was initially used for treating refractory
rejection based on the demonstration of intrarenal B-cell
infiltrates in both cell-mediated rejection (CMR) and AMR
[62]. The presence of B-cell infiltrates in acute rejection is a
risk factor for steroid resistance and is associated with a
worse prognosis. It is unclear whether the B cells present
within the allograft function as plasma-cell precursors,
antigen-presenting cells, and/or provide costimulatory
signals to T cells. B cells also produce inflammatory
cytokines that may directly injure the allograft. The effect
of rituximab on B-cell infiltration was reported in two
studies. Zarkhin et al. prospectively studied pediatric renal
transplant recipients who had biopsy proven CMR with B-
cell infiltrates [63]. Patients were randomized to receive
four weekly doses of rituximab (375 mg/m
2) plus standard
treatment versus standard treatment alone. The B-cell
infiltrate was abolished in all cases after rituximab
treatment, with improvement in renal function. Steinmetz
et al. identified nine patients with vascular allograft
rejection and B-cell clusters present in biopsy specimens
[64]. Patients who received one dose of rituximab (375 mg/m
2)
in addition to conventional treatment had complete
resolution of the B-cell infiltrate. Both studies were small,
and no differences were seen in clinical outcomes between the
groups. It is notable that complete resolution of the B-cell
infiltrate was seen whether patients received one dose of
rituximab or four.
Many recent reports support the clinical efficacy of
rituximab for treating AMR. Becker et al. initially reported
the benefit of rituximab in treating refractory rejection [65].
The investigators evaluated 27 patients who received
rituximab for refractory AMR diagnosed by the presence
of thrombotic microangiopathy (TMA) or endotheliitis in
renal allograft biopsies. Patients received treatment with
steroids, PP, and/or antithymocyte globulin (ATG) without
improvement in creatinine prior to receiving a single dose
of rituximab (375 mg/m
2). There were three graft losses.
The 24 successfully treated patients had good allograft
function at the time of discharge after rituximab treatment.
Other recent reports also document a beneficial effect of
rituximab for refractory AMR [66–69].
Earlier reports did not clearly differentiate between CMR
and AMR. Indeed, in the case series reported by Steinmetz
et al. [64], seven of the nine patients had positive staining
for C4d. There are numerous case reports describing the
benefit of rituximab specifically for treating AMR. AMR
has classically been diagnosed by allograft dysfunction, the
presence of the complement fragment C4d in peritubular
capillaries (PTC), and identification of donor-specific or
antiendothelial-cell antibodies. The effectiveness of
rituximab is reported in combination with IVIG, PP, and/
or steroids [66, 68–73]. The ameliorative effects of
rituximab on AMR are likely multifactorial. In addition to
B-cell depletion and reduced DSA, disruption of T-cell
costimulator and APC activities mediated by B cells are
likely altered and result in diminished T-cell effector
functions. Optimal treatment of AMR probably requires a
combination of rituximab with PP and low-dose IVIG or
with high-dose IVIG (1–2 gm/kg) due to the inability of
rituximab to deplete CD20-negative plasma cells that
continue to produce DSA and mediate graft injury.
Our center has extensive experience with HS patients
who received kidney transplants after desensitization with
IVIG and rituximab [7]. Recently, we evaluated 123 HS
patients transplanted after desensitization (July 2006
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AMR posttransplant, usually within the first month. All
were treated with a combination of steroids (10 mg/kg
daily x 3), IVIG 2 g/kg (maximum dose 140 g × 1), and
rituximab (375 mg/m
2 × 1). Some patients also received PP,
and two underwent splenectomy. Six of 22 patients (27%)
lost their allograft to severe AMR, usually within 1 month.
Thus, a 73% survival rate for severe AMR was seen in this
high-risk group [73].
Kaposztas et al. reported 2-year outcomes in their recent
retrospective study looking at 54 patients treated for AMR
[66]. Group A had 26 patients who underwent treatment
with PP and rituximab, and group B had 28 patients who
received PP without rituximab. Patients who had low serum
IgG levels also received IVIG. Two-year graft survival was
significantly better in the group that received rituximab
(90% vs 60%), with the difference attributed to rituximab.
A trend toward improved graft survival was also seen in
those who received IVIG (p=0.050). This retrospective
study has one of the largest cohorts reported to date and
supports the use of rituximab for treating AMR, with good
short-term allograft survival; however, many patient
variables were not consistent between the groups. Mulley
et al. [69] recently reported a case series of seven patients
with refractory AMR who responded to treatment with a
single low dose of rituximab (500 mg). All patients
recovered renal function, with patient and graft survivals
at a mean 21 months’ follow-up of 100%. Three patients
had significant viral infections, but all recovered. Recent
data from experimental primate islet transplants show
that the addition of B-cell depletion to standard immuno-
suppression results in significant prolongation of islet
allograft survival, with inhibition of alloantibody responses
[74]. In addition, Kessler et al. [75] recently reported the
complete reversal of an AMR episode of an islet transplant
using the combination of IVIG + rituximab. Complete
DSA ablation was also noted in association with allograft
recovery.
Therapeutic options treating AMR
Based on our experience [14, 73] and a review of the
literature, we propose the following treatment approaches
for AMR management. Patients who develop allograft
dysfunction associated with risk factors for acute AMR
(DSA positivity, history of desensitization, previous trans-
plants) and show biopsy evidence of antibody-mediated
injury (C4d+) with minimal pathologic features [acute
tubular necrosis (ATN)-like minimal changes] are treated
with a combination of pulse methylprednisolone, high-dose
IVIG (2 g/kg), and rituximab (375 mg/m
2 × 1) (Fig. 4).
This approach is usually sufficient to reverse most AMR
episodes with the clinical and pathological features de-
scribed above.
Patients who present with more severe clinical features
(rapid cessation of renal function posttransplant associated
with diffuse C4d+ staining, DSA positivity, and evidence of
capillary and/or glomerular inflammation with thrombosis)
are best treated with plasma exchange followed by IVIG
and rituximab (Fig. 5). The most important clinical
determinant of which protocol to use is the rapidity of
onset of graft dysfunction posttransplant. It is important to
understand that therapy should be instituted rapidly in the
at-risk population, even if DSA levels and renal biopsy
results are not available. Delays in treatment initiation can
result in irreversible graft loss. The most important
preventative measure in desensitized patients is to proceed
to transplant only after DSA levels have fallen into what is
considered an acceptable range. This is critical, as CMX
and DSA levels are rarely negative by traditional standards
after desensitization. Thus, proper patient preparation for
incompatible transplantation is the best assurance that AMR
is not likely to occur (Figs. 1 and 2)[ 7, 15]. The above
protocols are those developed at our institution and by no
means are the only way to approach AMR treatment. A
more definitive summary of other approaches has been
recently published [18].
Fig. 4 Cedars-Sinai Medical
Center protocol for treating
antibody-mediated rejection
(AMR) that is C4d+. After
AMR diagnosis by biopsy,
patients are treated with pulse
Solumedrol (SM) (10 mg/kg)
daily × 3 on day 1 and
intravenously administered
immunoglobulin (IVIG) 2 g/kg
(maximum dose 140 g),
followed on day 2 by rituximab
375 mg/m
2 . A repeat IVIG dose
is usually given at 30–60 days
after AMR diagnosis
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Chronic antibody-mediated rejection (CAMR) is defined by
criteria set forward in Banff in 2007 [15]. CAMR has a
poor prognosis, with no well-defined treatment protocol. A
pilot study, conducted by Billing et al., investigated the use
of IVIG with rituximab in six patients (ages 10–26) who
had evidence of CAMR [76]. The patients received four
weekly doses of IVIG (1 g/kg) followed by one dose of
rituximab (375 mg/m
2). All patients showed >40% positive
C4d staining of PTC. All biopsies had varying degrees of
CD20-positive infiltrates. Allograft function stabilized or
improved in four patients after 1 year of observation. There
was one graft loss at 18 months, and one patient did not
respond. Five out of six patients had complete depletion
of B cells in the peripheral blood. The two patients who
did not respond had the highest degree of transplant
glomerulopathy. Fehr et al. [74] recently reported a group
of four patients with CAMR who were treated with a
combination of IVIG + rituximab. All four patients had
significant clinical improvement, although one patient
developed an acute rejection episode 12 months later. One
patient also developed what was described as rituximab-
associated lung toxicity, which resolved. The authors
concluded that this approach may represent an important
treatment for CAMR. Our experience is similar to the
above case reports. Data from two patients with CAMR are
shown in Fig. 6. Briefly, both patients underwent desensi-
tization >3 years before proteinuria onset. Neither patient
had impaired renal function, but significant biopsy findings
were seen, and both had significant elevations in DSA
levels associated with the proteinuria. As can be seen from
the figure, both patients had significant reductions in DSA
levels after treatment with IVIG + rituximab and continue
to show normal kidney function with reductions in
proteinuria.
In summary, reports have demonstrated the efficacy of
rituximab for treating refractory rejections, rejection that
contains B-cell infiltrates, AMR, and CAMR. The available
evidence suggests improved creatinine and allograft
survival in the short- and medium term. The combination
of IVIG + rituximab appears to be a promising approach to
reduce DSA and treat AMR and CAMR [76, 77].
Plasmapheresis has an important role in managing rapid-
onset AMR associated with TMA or other significant
pathologic features of vasculitis. Clearly, the combination
of these therapies appears to have benefits over the use of
any one agent alone. As more data are accumulated, a better
understanding of how to construct treatment paradigms will
emerge.
Evolving approaches treating AMR
Bortezomib
Bortezomib is a modified dipeptidyl boronic acid analog
that binds selectively and reversibly to the 26S proteasome.
Proteasomes are abundant in both the cytoplasm and
nucleus of cells and act to degrade ubiquitinated proteins
Fig. 5 Cedars-Sinai Medical Center protocol for treating more severe
antibody-mediated rejection (AMR) associated with glomerular
thrombi and graft dysfunction [thrombotic microangiopathy (TMA)].
Here, early plasmapheresis (PP) is essential to remove antibody and
other inflammatory mediators before treatment with intravenously
administered immunoglobulin (IVIG) and rituximab. In our protocol,
we do not use low-dose IVIG after each plasmapheresis but replace it
with albumin and fresh-frozen plasma. IVIG 2g/kg (maximum dose
140 g) is given at the completion of plasmapheresis treatment,
followed by rituximab 375 mg/m
2. Renal function and donor-
specific antibodies (DSA) are monitored posttreatment
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of Kappa B (ikB) degradation, subsequently allowing
nuclear factor Kappa B (NF-κB) signal transduction in
the nucleus. This important signaling pathway is critical for
transducing nuclear signals of most cytokines. Inhibition of
the 26S proteasome prevents degradation of key proteins
and affects multiple signaling cascades within the cell,
which ultimatelylead tocell death viaapoptosis. Bortezomib
acts in the bone marrow microenvironment by inhibiting the
binding of myeloma cells to bone marrow stromal cells.
Importantly, bortezomib causes plasma-cell apoptosis in
bone marrow, which can inhibit antibody production [78].
Bortezomib also has an anabolic effect on bones, inhibiting
human osteoclast activity and stimulating osteoblast func-
tion. Bortezomib is primarily metabolized by cytochrome
P450 (CYP) enzymes CYP3A4, CYP2C19, and CYP1A2,
with a minor amount of metabolism occurring via
CYP2D6 and CYP2C9. The most frequently reported
adverse events (incidence ≥30%) associated with the use
of bortezomib are asthenic conditions (fatigue, weakness,
malaise), gastrointestinal events (nausea, diarrhea, consti-
pation, vomiting), peripheral neuropathy, pyrexia, thrombo-
cytopenia, neutropenia, psychiatric disorders, and anorexia/
decreased appetite. Drug-related adverse events could
generally be managed by dosage modifications and sup-
portive therapy [78].
A few reports have emerged regarding the use of
bortezomib for modifying anti-HLA antibodies and treating
cell-mediated and AMR episodes [79, 80]. Although the
reports are of very small numbers of patients, the inves-
tigators found that bortezomib was effective in reducing anti-
HLA antibody levels and reversing both cell-mediated and
AMR episodes in all patients treated. Long-term follow-up
was not available on these patients, but some patients had
recurrence of anti-HLA antibody titers after treatment. These
two studies are also complicated by the use of more standard
therapies (plasmapheresis, ATG, rituximab, and IVIG) for
these patients, as well. The authors also reported no
significant adverse events with bortezomib therapy, contrast-
ing with the relatively high AE profile reported in treating
myeloma patients [78]. Clearly, more studies at multiple
centers are required before this therapy can be recommended
for AMR desensitization or treatment, but these reports
cautiously suggest that bortezomib may have an important
role in treating AMR in the future.
Eculizumab: an inhibitor of complement activation
Eculizumab (Alexion, Cheshire, CT, USA) is a humanized
monoclonal antibody that binds to and subsequently
prevents activation of C5 by the amplified C3 convertase
molecules [81]. As a consequence of this inhibition, the
generation of the phlogistic C5a anaphylatoxin and forma-
tion of the C5b-C9 membrane attack complex [C5b-C9
membrane attack complex (MAC)] is prevented. Eculizumab
is approved by the US Food and Drug Administration for
treating paroxysmal nocturnal hemoglobinemia (PNH) only,
but there is a great deal of interest in investigating this
Fig. 6 Outcomes of two
patients who developed class II
donor-specific antibodies
(DSA) 3–4 years posttransplant
associated with the onset of
proteinuria with minimal
changes in allograft function.
The biopsy for one patient is
shown, but both patients had
similar findings of transplant
glomerulopathy. Both patients
showed a significant reduction
in class II DSAs, with stabiliza-
tion of renal function and some
reduction in proteinuria after
treatment with intravenously
administered immunoglobulin
(IVIG) + rituximab
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ment activation plays an important role in pathogenesis.
One of the principal goals of desensitization is to reduce
DSA levels to a point where accommodation will occur
rather than AMR with graft loss. This is often a delicate
balance that is not well understood. Accommodation refers
to a process where DSA interacts with targets on vascular
endothelium of the allograft but does not cause injury.
Eventually, the allograft “accommodates” to the antibody
and is able to maintain good function without evidence of
allograft injury. Williams et al. [82] have shown that the
difference between accommodation and AMR is the level
of complement activation. In experimental models of
xenotransplantation, the grafts that underwent AMR and
loss showed deposition of all complement components,
including C4d and—more importantly—C5b-C9 MAC.
However, xenografts that demonstrated accommodation
showed C4d deposits only. The authors concluded that
incomplete complement activation by antibody is critical
for accommodation development. Complement activation
plays a critical role in mediating AMR after kidney
transplantation. As eculizumab has the ability to inhibit
C5b-C9 MAC and C5a generation, it should act as a strong
accommodation promoter and prevent AMR. Fortunately,
recent data presented by Stegall et al. [83] supports this
contention. These investigators treated ten patients who
underwent desensitization with plasmapheresis + IVIG with
eculizumab after transplantation. Traditionally, the expected
rate of AMR in this group of patients was 31–39%. After
nearly 12 months of follow-up for all patients, none
developed AMR. Several protocol biopsies showed C4d
deposits but no evidence of AMR. This finding is
suggestive of incomplete complement activation, which is
permissive for accommodation. There were no significant
adverse events associated with eculizumab use. Overall,
this study is very encouraging, and this unique monoclonal
antibody may add significantly to our armamentarium of
agents to prevent and treat AMR. As current therapies for
AMR desensitization and treatment are aimed at reducing
pathogenic antibodies, it is not unreasonable to assume
that the addition of a monoclonal antibody such as
eculizumab, which inhibits terminal effectors, would act
in concert with our established therapies. For example, a
combination of high-dose IVIG + eculizumab could act to
modify elements of cellular immunity, humoral immunity,
and complement effectors. Confirmation of these ideas
awaits clinical trials.
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Questions:
(Answers appear following the reference list)
1. Which of the following is NOT a characteristic of
antibody-mediated rejection (AMR)?
a. C4d deposition
b. Thrombotic microangiopathy
c. DSA detection
d. T-cell infiltrates
e. Rapid onset of allograft dysfunction
2. The most up to date way for detecting DSA is the use
of CDC assays.
a. True
b. False
3. When dealing with suspected AMR in a highly-HLA
sensitized patient, the most important aspect is to wait
for biopsy results before initiation of antirejection
therapy for AMR.
a. True
b. False
4. Which of the following would NOT be considered a
primary therapy for treatment of AMR?
a. Plasmapheresis + low-dose IVIG
b. Thymoglobulin
c. Rituximab
d. High-dose IVIG
e. High-dose IVIG + rituximab
5. Chronic allograft nephropathy (CAN) is not mediated
by immunologic mechanisms.
a. True
b. False
6. Newer approaches to preventing and treating AMR
include bortezomib and anticomplement therapies.
a. True
b. False
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